CDR132L
Antisense RNA medical therapy
From Wikipedia, the free encyclopedia
CDR132L is an antisense RNA therapy that inhibits MiR-132. It is developed by Cardior Pharmaceuticals to treat heart failure.[1][2][3]
Antisense RNA medical therapy
From Wikipedia, the free encyclopedia
CDR132L is an antisense RNA therapy that inhibits MiR-132. It is developed by Cardior Pharmaceuticals to treat heart failure.[1][2][3]